Literature DB >> 7570844

The effect of ivermectin treatment on the antibody response to antigens of Onchocerca volvulus.

A J Gillespie1, S Lustigman, A R Rivas-Alcala, J E Bradley.   

Abstract

The effect of the microfilaricidal drug ivermectin on the antibody response to a detergent extract of adult Onchocerca volvulus (OvAg) and a number of specific recombinant peptides was examined. Three of the peptides were combined in a serodiagnostic 'cocktail' and the effect of ivermectin on the diagnostic performance of this assay was assessed. Immunoglobulin (Ig) G1 serum levels in response to OvAg significantly decreased following ivermectin treatment. The antibody response to only one recombinant peptide (OvMBP29) was significantly affected, with IgG levels decreasing following treatment. Levels of total IgE increased following treatment. No correlation was observed between initial antibody level (or change in antibody level) and any adverse reaction to treatment. The serodiagnostic 'cocktail' was 100% sensitive before and after the use of ivermectin. A serodiagnostic assay using specific recombinant peptides can be used to evaluate infection in the absence of dermal microfilariae in areas where ivermectin is used.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7570844     DOI: 10.1016/0035-9203(94)90433-2

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  3 in total

1.  Immunoglobulin G subclass responses of children during infection with Onchocerca volvulus.

Authors:  A A Gbakima; T B Nutman; J E Bradley; L A McReynolds; M D Winget; Y Hong; A L Scott
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

2.  Population biology of human onchocerciasis.

Authors:  M G Basáñez; M Boussinesq
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-04-29       Impact factor: 6.237

3.  Prediction and validation of the structural features of Ov58GPCR, an immunogenic determinant of Onchocerca volvulus.

Authors:  Robert Adamu Shey; Stephen Mbigha Ghogomu; Ferdinand Ngale Njume; Lea Olive Tchouate Gainkam; Philippe Poelvoorde; Leon Mutesa; Annie Robert; Perrine Humblet; Jean-Pierre Munyampundu; Joseph Kamgno; Christophe Lelubre; Luc Vanhamme; Jacob Souopgui
Journal:  PLoS One       Date:  2018-09-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.